Comparing Amneal Pharmaceuticals (NASDAQ:AMRX) and Golden Dragon (OTCMKTS:CPMD)

Amneal Pharmaceuticals (NASDAQ:AMRX) and Golden Dragon (OTCMKTS:CPMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Institutional & Insider Ownership

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Golden Dragon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Amneal Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Golden Dragon has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Amneal Pharmaceuticals and Golden Dragon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0	2	6	0	2.75
Golden Dragon	0	0	0	0	0.00

Amneal Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 7.84%. Given Amneal Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Amneal Pharmaceuticals is more favorable than Golden Dragon.

Profitability

This table compares Amneal Pharmaceuticals and Golden Dragon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	2.39%	-228.24%	6.91%
Golden Dragon	-816.80%	N/A	-107.71%

Earnings and Valuation

This table compares Amneal Pharmaceuticals and Golden Dragon”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02 billion	1.45	$72.06 million	$0.23	60.48
Golden Dragon	$1.36 million	1.94	-$11.13 million	($0.01)	-0.39

Amneal Pharmaceuticals has higher revenue and earnings than Golden Dragon. Golden Dragon is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amneal Pharmaceuticals beats Golden Dragon on 11 of the 14 factors compared between the two stocks.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

About Golden Dragon

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.